CytomX Therapeutics, Inc. (NASDAQ:CTMX) Sees Significant Decrease in Short Interest

CytomX Therapeutics, Inc. (NASDAQ:CTMX) was the target of a large decrease in short interest during the month of September. As of September 30th, there was short interest totalling 6,250,000 shares, a decrease of 10.5% from the September 15th total of 6,980,000 shares. Based on an average trading volume of 686,500 shares, the short-interest ratio is currently 9.1 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “neutral” rating on shares of CytomX Therapeutics in a research report on Friday, September 13th. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $5.77.

Hedge Funds Weigh In On CytomX Therapeutics

Large investors have recently made changes to their positions in the company. SG Americas Securities LLC acquired a new stake in CytomX Therapeutics in the first quarter worth about $57,000. Susquehanna Fundamental Investments LLC acquired a new stake in shares of CytomX Therapeutics during the 1st quarter worth approximately $124,000. Acadian Asset Management LLC raised its stake in shares of CytomX Therapeutics by 1.7% during the first quarter. Acadian Asset Management LLC now owns 2,690,830 shares of the biotechnology company’s stock worth $5,863,000 after buying an additional 44,640 shares during the last quarter. Congress Park Capital LLC lifted its holdings in CytomX Therapeutics by 393.3% in the second quarter. Congress Park Capital LLC now owns 1,153,220 shares of the biotechnology company’s stock valued at $1,407,000 after buying an additional 919,420 shares during the period. Finally, Assenagon Asset Management S.A. boosted its stake in CytomX Therapeutics by 206.0% in the second quarter. Assenagon Asset Management S.A. now owns 1,238,499 shares of the biotechnology company’s stock valued at $1,511,000 after acquiring an additional 833,825 shares during the last quarter. Institutional investors and hedge funds own 67.77% of the company’s stock.

CytomX Therapeutics Stock Performance

Shares of NASDAQ CTMX traded down $0.02 during trading on Thursday, reaching $1.16. The company had a trading volume of 392,745 shares, compared to its average volume of 2,682,713. CytomX Therapeutics has a 52 week low of $1.04 and a 52 week high of $5.85. The business’s 50 day moving average price is $1.19 and its 200-day moving average price is $1.58. The stock has a market cap of $90.39 million, a PE ratio of 5.80 and a beta of 1.04.

CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The company had revenue of $25.12 million during the quarter, compared to the consensus estimate of $21.79 million. CytomX Therapeutics had a negative return on equity of 27.44% and a net margin of 9.27%. During the same quarter last year, the firm earned ($0.02) EPS. Equities analysts anticipate that CytomX Therapeutics will post -0.29 earnings per share for the current year.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.